#AANAM – Investigational DM1 Therapy Shows Promise

#AANAM – Investigational DM1 Therapy Shows Promise

Editor’s note: The Muscular Dystrophy News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. An investigational therapy called AOC-1001 decreased levels of the toxic RNA molecule that causes…

How I’ve Managed Constipation as Someone With Duchenne

This is the dirtiest column I have ever written because it’s about poop. And whether you love it or hate it, it’s an especially relevant topic to the Duchenne muscular dystrophy community. Sitting in a wheelchair for long periods and experiencing overall muscle weakness can…

FDA Places Pamrevlumab for DMD on Fast Track

The U.S. Food and Drug Administration has granted fast track designation to pamrevlumab, an investigational treatment for Duchenne muscular dystrophy (DMD). The designation is given to medications that have the potential to treat serious conditions and to fill an unmet medical need. The designation allows the therapy’s developer, FibroGen,…